FOR IMMEDIATE RELEASE
Contact:
Ranbaxy Pharmaceuticals Selects In.vision Xpress Author for Production of
Structured Product Labels (SPL) Under the Physician’s Labeling Rule (PLR) Saint
Petersburg, Florida May 29, 2007. In.vision Research Corporation, the leading provider of software for enterprise
XML authoring, announced today that Ranbaxy Pharmaceuticals has joined the
growing list of companies that have selected Xpress Author for Microsoft Word to
prepare Structured Product Labels (SPL) according to the Physicians Labeling
Rule. A
2006 New York Times
article reported that studies show approximately 300,000 people are injured
and nearly 100,000 are killed in hospitals every year because of medical errors,
with prescribing errors being a major cause. According to the Times, studies
also show that fewer than one in 10 physicians routinely read drug labels, and
when they do read labels, the information is not easily assimilated. The
Physician’s Labeling Rule is designed to help the primary users of prescribing
information, healthcare professionals. The FDA evaluated the usefulness of
prescribing information among healthcare professionals to determine whether and
how communication could be improved. After broad consultation with the public
and industry, it was clear that prescribing information could be more effective
in communicating drug information and there was overwhelming support for FDA's
goal of improving the content and format and for the proposed reordering of
sections. About
Ranbaxy
Ranbaxy Pharmaceuticals Incorporated, is a wholly owned subsidiary of RLL,
India’s largest pharmaceutical company. RPI is engaged in the sale and
distribution of generic and branded prescription products in the U.S. healthcare
system. About
In.vision
Founded in 1996,
In.vision Research Corporation is the leading provider of software for
Enterprise XML Authoring. In.vision's Xpress Author products enable
Microsoft Word users to easily and transparently produce XML content, making
In.vision the clear choice for today's business authors. In.vision customers
create content that is critical to national security, prescription drug
safety, publishing processes, financial services, and enterprise content
management. With corporate offices in both the U.S. and Europe, In.vision
delivers and supports its products through a global network of industry
focused business partners. For more information on In.vision, please visit
www.invisionresearch.com
David Dalton
Business Development Manager
In.vision research Corp.
ddalton@invisionresearch.com
(727) 822-7200
“Once
again we are pleased to see a major pharmaceutical company recognize the ability
of Xpress Author to optimize their internal submission processes,” said John
Friske, In.vision CEO. “As an established leader in this field, it appears that
In.vision has now delivered more licenses for the authoring of structured
product labels than all other vendors combined. This is an important industry
role and one that we take seriously.”
Ranbaxy Laboratories Limited, India's largest pharmaceutical company,
headquartered in India, is an integrated, research based, international
pharmaceutical company producing a wide range of quality, affordable generic
medicines, trusted by healthcare professionals and patients across geographies.
Ranbaxy’s continued focus on R&D has resulted in several approvals in developed
markets and significant progress in New Drug Discovery Research. The Company is
serving its customers in over 125 countries and has an expanding international
portfolio of affiliates, joint ventures and alliances, ground operations in 49
countries and manufacturing operations in 11 countries. For more information
about Ranbaxy, please visit
www.ranbaxy.com